• On June 1, 2020, Emergent announced a $628 million contract with the U.S. government to produce COVID-19 vaccines.
• The company started producing vaccine materials for Johnson & Johnson and AstraZeneca at its Baltimore facility in late 2020. 
• In March 2021, the facility accidentally contaminated Johnson & Johnson vaccine doses with AstraZeneca ingredients. 
• By April 2021, the FDA halted production at the site, citing quality issues, contamination risks, and poor training.
• Following the contamination crisis, Emergent stock price dropped by over 60% by November 2021, erasing over half the company’s market value in just months.
• Shortly after, shareholders filed multiple lawsuits against Emergent, claiming the company misrepresented its vaccine production capabilities and hid serious quality issues.
• Emergent BioSolutions recently agreed to pay a $40 million settlement to investors to resolve the lawsuits. Affected investors can now file a claim to receive the payout.

Overview

Emergent BioSolutions EBS secured over $1 billion in government and pharmaceutical contracts during the COVID-19 pandemic. However, in March 2021, workers at its Baltimore facility mistakenly mixed Johnson & Johnson and AstraZeneca vaccine ingredients, contaminating up to 15 million J&J doses and forcing AstraZeneca to discard tens of millions more. This error delayed J&J’s vaccine rollout and disrupted global distribution, causing Emergent stock to drop by over 50% by November 2021. Following these events, a group of shareholders sued Emergent, and recently, Emergent agreed to pay a $40 million settlement to all affected investors.

How It All Started: Manufacturing Failures 

In the wake of the COVID-19 pandemic, Emergent BioSolutions positioned its Bayview facility as a critical vaccine production asset. In March 2020, the company secured over $1 billion in contracts with Johnson & Johnson and AstraZeneca, including a substantial government Operation Warp Speed contract.

On April 30, 2020, CEO Robert Kramer declared during an earnings call that the company had “proven manufacturing capabilities” and was prepared to scale up quickly to meet the demands of vaccine production. 

In July 2020, following the AstraZeneca agreement, Emergent further bolstered its claims in a press release, with Kramer declaring, “Emergent is driven by our desire to advance solutions that will make an impact on this pandemic“. 

The company’s CDMO business unit head, Syed T. Husain, added that “Emergent stands ready alongside leading innovators to rapidly deploy our CDMO services to help meet the substantial demand for a vaccine.“

By early 2021, Emergent shares were trading above $90, fueled by high expectations for the company’s role in vaccine production. 

However, despite positive public messaging, internal audits and inspections in the summer of 2020 uncovered serious issues at Emergent BioSolutions’ manufacturing facilities. 

Reports highlighted poor staff training, equipment failures, and inadequate quality control measures, revealing long-standing problems within the company’s operations. One audit found that “the flow of workers and materials through the plant was not adequately controlled to prevent mix-ups or contamination.” Another audit discovered that a manager had “knowingly deviated” from standard procedures.

After that, in November 2020, AstraZeneca representatives visiting Emergent’s Bayview facility raised concerns about poor oversight and GMP compliance. 

Emergent’s VP of Manufacturing acknowledged these issues, mentioning trash buildup in hallways and lapses in GMP standards. An external consultant also warned that the facility was “NON-CGMP compliant” and at regulatory risk, but production still continued.

Contamination Crisis at Emergent’s Facility

In March 2021, a major contamination incident at Emergent’s Baltimore facility revealed significant oversight failures. Millions of Johnson & Johnson vaccine doses were mixed with AstraZeneca ingredients, an issue initially detected by Johnson & Johnson’s lab in the Netherlands, not Emergent. 

The contamination forced the disposal of tens of millions of AstraZeneca doses and delayed the delivery of approximately 100 million Johnson & Johnson doses during a critical phase of the pandemic. 

Following this disclosure, Emergent issued a press release, stating that their “quality control systems worked as designed” and that discarding a batch of bulk drug substance “occasionally happens during vaccine manufacturing.” 

However, that same day the Associated Press released FDA documents obtained through FOIA requests, revealing a history of quality control issues at Emergent’s facilities dating back to 2017.

FDA leaders reported that the company “hired a lot of individuals not as familiar with vaccine manufacturing that did not have adequate training.” 

Inspectors found several issues at Emergent’s facility, including mismanaged waste, peeling paint, and cluttered equipment. They also discovered that some quality checks were removed from vaccines before an FDA visit in February 2021. 

Later, it came to light that Emergent had been forced to destroy vaccine materials equivalent to nearly 400 million doses — much more than the previously reported 85 million.

The situation worsened on November 4, 2021, when Emergent announced that the Department of Health and Human Services had cancelled its $628 million contract, requiring the company to reverse $86 million in Q3 2021 revenue and reduce its contract backlog by $180 million.

The impact on investors was clear as Emergent’s stock price dropped by over 60%, from more than $120 in early 2021 to below $45 by November 2021.

These disclosures and the sharp drop in stock price led shareholders to file multiple lawsuits against Emergent, accusing the company of misrepresenting its vaccine production capabilities and concealing serious quality issues.

Resolving The Case

After three years of legal proceedings, in September 2024, Emergent agreed to pay $40 million to settle the lawsuit from shareholders. If you invested in Emergent, you may be eligible to file for a portion of the settlement to recover your losses.

As of now, Emergent BioSolutions has made significant progress in its recovery, securing a $50 million settlement with Johnson & Johnson and driving a broader transformation under CEO Joe Papa. In Q3 2024, the company saw a 9% revenue increase to $293.8 million and secured vital government contracts, including a $250 million order to produce vaccines for anthrax, botulism, and smallpox. It also sold its Camden facility for $30 million to streamline operations. However, its stock remains far below previous highs, trading at $8 in November 2024 — a 93.6% decline from its $125 peak in 2021, showing that there is still a long road ahead for a recovery.